VIATRIS INC. Payments to Acquire Marketable Securities
VIATRIS INC. (VTRS) reported Payments to Acquire Marketable Securities of $16.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- VIATRIS INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $9.30M, a 47.62% increase year-over-year.
- VIATRIS INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $7.50M, a 63.04% increase year-over-year.
- VIATRIS INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $5.80M, a 34.88% increase year-over-year.
- VIATRIS INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $7.20M, a 14.29% decline year-over-year.
- VIATRIS INC. payments to acquire marketable securities for fiscal 2025 was $23.90M, a 8.08% decline from fiscal 2024.
- VIATRIS INC. payments to acquire marketable securities for fiscal 2024 was $26.00M, a 1.14% decline from fiscal 2023.
- VIATRIS INC. payments to acquire marketable securities for fiscal 2023 was $26.30M, a 12.91% decline from fiscal 2022.
- VIATRIS INC. payments to acquire marketable securities for fiscal 2022 was $30.20M, a 0.00% change from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.80M 10-Q · filed 2026-08-06 | $22.60M derived: sum of 3 quarters · filed 2026-08-06 | $29.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.50M 10-Q · filed 2026-05-07 | $13.30M derived: sum of 2 quarters · filed 2026-05-07 | $20.50M derived: sum of 3 quarters · filed 2026-05-07 | $26.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.00M derived: sum of 2 quarters · filed 2026-02-26 | $19.30M derived: sum of 3 quarters · filed 2026-08-06 | $23.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.50M derived: sum of 2 quarters · filed 2026-08-06 | $18.10M 10-Q · filed 2025-11-06 | $22.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $6.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.90M 10-Q · filed 2026-08-06 | $15.20M derived: sum of 3 quarters · filed 2026-08-06 | $23.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.60M 10-Q · filed 2026-05-07 | $8.90M derived: sum of 2 quarters · filed 2026-05-07 | $17.30M derived: sum of 3 quarters · filed 2026-05-07 | $22.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.70M derived: sum of 2 quarters · filed 2026-02-26 | $18.30M derived: sum of 3 quarters · filed 2026-02-26 | $26.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.00M derived: sum of 2 quarters · filed 2025-11-06 | $21.70M 10-Q · filed 2025-11-06 | $27.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.30M 10-Q · filed 2025-08-07 | $18.70M derived: sum of 3 quarters · filed 2026-02-26 | $23.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $7.70M 10-Q · filed 2025-05-08 | $13.10M derived: sum of 2 quarters · filed 2026-02-26 | $17.40M derived: sum of 3 quarters · filed 2026-02-26 | $25.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.70M derived: sum of 2 quarters · filed 2026-02-26 | $17.30M derived: sum of 3 quarters · filed 2026-02-26 | $26.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $11.90M derived: sum of 2 quarters · filed 2024-11-07 | $20.90M 10-Q · filed 2024-11-07 | $27.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $7.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $16.60M 10-Q · filed 2024-08-08 | $23.50M derived: sum of 3 quarters · filed 2025-02-27 | $33.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $9.00M 10-Q · filed 2024-05-09 | $15.90M derived: sum of 2 quarters · filed 2025-02-27 | $26.00M derived: sum of 3 quarters · filed 2025-02-27 | $30.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $17.00M derived: sum of 2 quarters · filed 2025-02-27 | $21.60M derived: sum of 3 quarters · filed 2025-02-27 | $30.20M 10-K · filed 2025-02-27 |
| 2022-09-30 | $10.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $14.70M derived: sum of 2 quarters · filed 2023-11-08 | $23.30M 10-Q · filed 2023-11-08 | $27.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $13.20M 10-Q · filed 2023-08-07 | $17.10M derived: sum of 3 quarters · filed 2024-02-28 | $23.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $8.60M 10-Q · filed 2023-05-08 | $12.50M derived: sum of 2 quarters · filed 2024-02-28 | $19.30M derived: sum of 3 quarters · filed 2024-02-28 | $26.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $10.70M derived: sum of 2 quarters · filed 2024-02-28 | $17.90M derived: sum of 3 quarters · filed 2024-02-28 | $30.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $6.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $14.00M derived: sum of 2 quarters · filed 2022-11-07 | $26.30M 10-Q · filed 2022-11-07 | $35.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $7.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $19.50M 10-Q · filed 2022-08-08 | $28.20M derived: sum of 3 quarters · filed 2023-02-27 | $34.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $12.30M 10-Q · filed 2022-05-09 | $21.00M derived: sum of 2 quarters · filed 2023-02-27 | $26.90M derived: sum of 3 quarters · filed 2023-02-27 | $63.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $14.60M derived: sum of 2 quarters · filed 2023-02-27 | $51.20M derived: sum of 3 quarters · filed 2023-02-27 | $104.80M 10-K · filed 2023-02-27 |
| 2020-09-30 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $42.50M derived: sum of 2 quarters · filed 2021-11-08 | $96.10M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $36.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $90.20M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $53.60M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $25.80M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $63.40M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |